Happy to see our paper describing the activity and MoA of a humanized MAb (VX-01) against mucormycosis published in Sciences Translational Medicine. This takes us a step closer to clinical testing on the road to provide better care for this lethal fungal infection.

New research has identified albumin — the most abundant protein in human blood — as a powerful natural defense against mucormycosis, a rare but often deadly fungal infection. 🧫 “This is a remarkable finding and has the potential to change the way clinicians care for mucormycosis,” said TLI Investigator @IbrahimLab3, senior author of the study published in @Nature. The discovery opens promising pathways for albumin-based therapies and targeted immunotherapies, offering hope for patients facing this often-fatal disease. Read the full story: bit.ly/4r9Ckcl #MedicalBreakthrough #MedicalFindings #InfectiousDisease #BiomedicalResearch #Mucormycosis #GlobalHealth #PublicHealth #ScientificDiscovery

It is an honor to be the recipient of the 2025 Frank J. DeSantis Award from @the_lundquist. It was also a pleasure to share the progress we made at Vitalex on VXV-01 vaccine targeting Candida infections and humanized monoclonal VX-01 antibody targeting mucormycosis. Thank you!

The Lundquist Institute, together with its start-up company @VitalexBioscien, is proud to announce a significant advancement in fungal vaccine research.🔬 Supported by a highly competitive $40 million contract from the NIH’s @NIAIDNews, the team is moving its second-generation, dual-antigen vaccine candidate VXV-01 into Phase 1 clinical trials. "It is the culmination of years of work on our TLI technology platform and reflects our commitment to tackling high-impact infectious disease challenges," said Ashraf Ibrahim, PhD, TLI Investigator, VXV-01 Program Lead, and CEO of Vitalex Biosciences. Learn more about this breakthrough: bit.ly/48cBJA4 #FungalInfections #VaccineResearch #BiomedicalInnovation #InfectiousDiseases #ClinicalTrials #TranslationalScience #ScientificDiscovery #HealthInnovation

Honored to welcome @SenBillCassidy to @the_lundquist. I showed him @IbrahimLab3, where we study host–pathogen interactions, develop immunotherapies for mucormycosis, and advance vaccines against drug-resistant infections. Grateful for his support of biomedical research.

IT'S A TWO-FER! A huge congratulations to TLI Investigator @IbrahimLab3 for receiving the 43rd Kuwait Prize by the @KuwaitFAS. This prestigious award honors Kuwaiti and Arab scientists for their exceptional scientific and intellectual contributions on a global scale.🚀 Dr. Ibrahim was also awarded by @NIAIDNews with a multi-year NIH grant exceeding $11 Million to transform the diagnosis and treatment of the deadly #Mucormycosis.🔬 "This investment from NIAID validates two decades of collaborative research and positions us to finally outpace a disease that currently kills at least half of the patients it strikes," said Dr. Ibrahim. Read more: bit.ly/4eTPUf8 #innovation #medicalresearch #sciencenews

Mucormycosis is a fungal infection that causes severe disease and fatality, especially in immunocompromised individuals. While vaccines and immunotherapeutics have been available in combating viral and bacterial infections, approved antifungal immunotherapies are lacking. Thanks to @IbrahimLab3 and their team's #research published on @ScienceMagazine, we are advancing towards increasing the efficiency of current treatment options for Mucormycosis to improve patient outcomes — a major translational step. #medicalresearch #biomedicine #sciencetranslationalmedicine #immunotherapy

Mucormycosis is a fungal infection that causes severe disease and fatality. “Mucormycosis usually occurs in patients who suffer from weakened immune system, such as patients with poorly controlled diabetes, cancer patients undergoing chemotherapy, and transplant patients,” says TLI Investigator Ashraf Ibrahim, PhD. 🔬🧪 Learn more about the groundbreaking antibody Dr. Ashraf Ibrahim, Dr. Yiyou Gu, and the @IbrahimLab3 team has developed that could be a promising treatment to help fight mucormycosis: bit.ly/4iHC8x0 #medicalresearch #biomedicine #Immunotherapy #publications

Happy to see our paper describing the activity and MoA of a humanized MAb (VX-01) against mucormycosis published in Sciences Translational Medicine. This takes us a step closer to clinical testing on the road to provide better care for this lethal fungal infection.

A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response | Science Translational Medicine science.org/doi/10.1126/scit…

🔬✨ National Immunization Awareness Month✨🔬 This August, we spotlight the critical role of vaccines and immunotherapies in our fight against infectious diseases. Learn more about @IbrahimLab3's work and @the_lundquist below: instagram.com/p/C-6AZhTyhd8/…

That’s a wrap! After 3 weeks in L.A I just have thankful words for the fantastic and welcoming @IbrahimLab3. Loads of learning at @the_lundquist see you later California @BallouLab @MRCcmm #Collaboration #STEM #FungiFriday

@the_lundquist Investigator Ashraf Ibrahim, PhD, has been selected by the Medical Mycology Society of the Americas (MMSA) to receive the 2024 Billy H. Cooper Award for his continuous outstanding achievement in clinical mycology. TLI congratulates Dr Ibrahim for this high honor.

Congrats @kierenamarr @davidrandes Nathan Wiederhold @doctorfungus @IbrahimLab3 Bill Steinbach etc on this achievement!

Great seminar about #aspergillus by Gustavo Goldman, from @FungalSao at @the_lundquist

Vitalex Biosciences, a spinoff start-up company of The Lundquist Institute for Biomedical Innovation, is proud to announce today that its VX-01 monoclonal antibody program targeting the debilitating indication of mucormycosis has been awarded an SBIR Phase 2 grant from NIAID/NIH.

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections @IbrahimLab3 @Ana_Alastruey @Nkechi93564130 mdpi.com/1904744

Dr @IbrahimLab3 from @HarborUCLA_ID presenting potential novel #antifungals vs #mucor @IDWeek2022